Medications for Opioid Use Disorder Save Lives

Medications for Opioid Use Disorder Save Lives PDF Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309486483
Category : Medical
Languages : en
Pages : 175

Get Book Here

Book Description
The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.

Medications for Opioid Use Disorder Save Lives

Medications for Opioid Use Disorder Save Lives PDF Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309486483
Category : Medical
Languages : en
Pages : 175

Get Book Here

Book Description
The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.

Office-Based Buprenorphine Treatment of Opioid Use Disorder, Second Edition

Office-Based Buprenorphine Treatment of Opioid Use Disorder, Second Edition PDF Author: John A. Renner Jr., M.D.
Publisher: American Psychiatric Pub
ISBN: 1615370838
Category : Medical
Languages : en
Pages : 400

Get Book Here

Book Description
With a new foreword by Nora Volkow, Director of the National Institute on Drug Abuse, this second edition of Office-Based Buprenorphine Treatment of Opioid Use Disorder provides updated information on evidence-based treatment for opioid use disorder (OUD)-an increasingly important topic as the epidemic of opioid misuse and overdose deaths grows in the United States. Bulleted clinical pearls at the end of each chapter, as well as specific clinical recommendations and detailed case discussions throughout, make it easier for readers to retain knowledge and integrate it into their clinical practice. The guide also features sample documentation and scales, including a treatment contract and a patient consent, that can be used to model documents in practice. This new edition of Office-Based Buprenorphine Treatment has been updated to reflect DSM-5 language, and two additional chapters have been included: one that addresses other pharmacotherapies useful in treating OUD, including methadone and naltrexone, and another that discusses OUD treatment specifically with regard to women's health and pregnancy. A discussion of the Comprehensive Addiction and Recovery Act (CARA). Advice for working with Alcoholics Anonymous and Narcotics Anonymous. A discussion on integrating buprenorphine into residential and inpatient opioid treatment programs. -- Publisher.

Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder

Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder PDF Author: Substance Abuse Mental Health Services Administration/SAMHSA (U.S.)
Publisher: Government Printing Office
ISBN: 0160943752
Category : Medical
Languages : en
Pages : 398

Get Book Here

Book Description
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat opioid use disorder (OUD)—methadone, naltrexone, and buprenorphine—and provides guidance for healthcare professionals and addiction treatment providers on appropriate prescribing practices for these medications and effective strategies for supporting the patients utilizing medication for the treatment of OUD. The goal of treatment for opioid addiction or OUD is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential. This TIP also educates patients, families, and the general public about how OUD medications work and the benefits they offer. Related products: Medication-Assisted Treatment of Opioid Use Disorder: Pocket Guide A Shared Burden: The Military and Civilian Consequences of Army Pain Management Since 2001 Click our Alcoholism, Smoking & Substance Abuse collection to find more resources on this topic.

Handbook of Office-based Buprenorphine Treatment of Opioid Dependence

Handbook of Office-based Buprenorphine Treatment of Opioid Dependence PDF Author: John A. Renner
Publisher: American Psychiatric Publishing
ISBN: 9781585623693
Category : Buprenorphine
Languages : en
Pages : 0

Get Book Here

Book Description
The Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence will serve as a reliable guide for the addition of buprenorphine treatment into existing clinical practices, both for psychiatrists and other clinicians. Adopting a new treatment modality can be challenging, yet the need to expand treatment services to include buprenorphine is urgent -- and this book meets both challenges. The potential to improve the lives of patients with the disease of opioid addiction is great, and this book offers concrete and practical advice for managing patients in an office-based setting. This handbook * Highlights the importance of counseling as an essential component of quality buprenorphine treatment* Provides the dimensions of assessment and available treatment options to ensure that patients receive the appropriate intensity of care* Urges clinicians to locate therapists trained in cognitive-behavior therapy, motivational enhancement therapy, and 12-step facilitation* Stresses the importance of care coordination with treatment counselors in order to deliver maximally effective buprenorphine treatment Distinguished practicing psychiatrists, internists, and other clinical experts and researchers contribute their expertise with buprenorphine to this volume. It covers the subject matter thoroughly -- from the history of opioid abuse and assessment criteria for potential patients to clinical management and psychiatric comorbidity. Chapters provide succinct conclusions and clinical pearls summarizing content regarding, among other topics, * General opioid pharmacology and the efficacy and safety of buprenorphine treatment programs* Detailed information about the clinical use of buprenorphine* Clinical management strategies for successful integration of the medication into private practices* Medical management, logistical considerations, and opioid use by adolescents This handbook provides the tools and guidelines necessary to help providers cultivate a therapeutic environment for treating opioid addiction that minimizes problem behaviors and optimizes treatment outcomes. The requirements for setting up a successful office-based treatment program are provided in detail. A screening questionnaire for patients and sample informed consent forms are provided. Because there is flexibility in how the necessary elements can be incorporated into existing programs, providers will learn through this handbook how to tailor their opioid addiction treatment plan to the needs of their particular practice and patients. Case vignettes, charts, and tables make the subject matter easily accessible for readers ranging from students to well-established practitioners. Clinicians will find this handbook an invaluable resource for successfully treating an increasing number of patients who struggle with the disease of opioid addiction.

Federal Guidelines for Opioid Treatment Programs

Federal Guidelines for Opioid Treatment Programs PDF Author: U.S. Department of Health and Human Services
Publisher: Lulu.com
ISBN: 1794763538
Category : Reference
Languages : en
Pages : 84

Get Book Here

Book Description
The Federal Guidelines for Opioid Treatment Programs (Guidelines) describe the Substance Abuse and Mental Health Services Administration's (SAMHSA) expectation of how the federal opioid treatment standards found in Title 42 of the Code of Federal Regulations Part 8 (42 CFR � 8) are to be satisfied by opioid treatment programs (OTPs). Under these federal regulations, OTPs are required to have current valid accreditation status, SAMHSA certification, and Drug Enforcement Administration (DEA) registration before they are able to administer or dispense opioid drugs for the treatment of opioid addiction.

Office-based Buprenorphine Treatment

Office-based Buprenorphine Treatment PDF Author: Shelly R. Noe
Publisher:
ISBN:
Category : Buprenorphine
Languages : en
Pages : 82

Get Book Here

Book Description


Medications for Opioid Use Disorder

Medications for Opioid Use Disorder PDF Author:
Publisher:
ISBN: 9780160943775
Category : Drug addicts
Languages : en
Pages : 322

Get Book Here

Book Description


Clinical Manual of Youth Addictive Disorders

Clinical Manual of Youth Addictive Disorders PDF Author: Yifrah Kaminer, M.D., M.B.A.
Publisher: American Psychiatric Pub
ISBN: 1615372369
Category : Medical
Languages : en
Pages : 634

Get Book Here

Book Description
Thoroughly updated and expanded, the book focuses on the clinical implications of beginning substance use and the pathways to substance use disorders (SUDs) and coexisting disorders among adolescents and college-age emerging adults (ages 12--25 years). This new manual not only captures the advances made in the youth substance use and SUD domains covered in the previous manual, but also includes new and critically important topics that have emerged.

Interventions For Addiction

Interventions For Addiction PDF Author: Adam J. Gordon
Publisher: Elsevier Inc. Chapters
ISBN: 0128065710
Category : Psychology
Languages : en
Pages : 30

Get Book Here

Book Description


Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence

Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence PDF Author: World Health Organization. Department of Mental Health and Substance Abuse
Publisher: World Health Organization
ISBN: 9241547545
Category : Medical
Languages : en
Pages : 133

Get Book Here

Book Description
"These guidelines were produced by the World Health Organization (WHO), Department of Mental Health and Substance Abuse, in collaboration with the United Nations Office on Drugs and Crime (UNODC) a Guidelines Development Group of technical experts, and in consultation with the International Narcotics Control Board (INCB) secretariat and other WHO departments. WHO also wishes to acknowledge the financial contribution of UNODC and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to this project. " - p. iv